On the other hand, administration of galectin-9 increases the sensitivity of chronic myeloid leukemia to the BCR-ABL tyrosine kinase drug imatinib [336]. The gene discussed is LGALS9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.